Search

Sun Jae Yoo

Examiner (ID: 13861, Phone: (571)272-9074 , Office: P/1626 )

Most Active Art Unit
1626
Art Unit(s)
1609, 1626, 1622, 1621
Total Applications
1806
Issued Applications
1149
Pending Applications
163
Abandoned Applications
560

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 20452976 [patent_doc_number] => 12516026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Cabozantinib compositions and methods of use [patent_app_type] => utility [patent_app_number] => 19/265483 [patent_app_country] => US [patent_app_date] => 2025-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 30321 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265483 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/265483
Cabozantinib compositions and methods of use Jul 9, 2025 Issued
Array ( [id] => 20452976 [patent_doc_number] => 12516026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Cabozantinib compositions and methods of use [patent_app_type] => utility [patent_app_number] => 19/265483 [patent_app_country] => US [patent_app_date] => 2025-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 30321 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265483 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/265483
Cabozantinib compositions and methods of use Jul 9, 2025 Issued
Array ( [id] => 20136122 [patent_doc_number] => 20250243166 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/184689 [patent_app_country] => US [patent_app_date] => 2025-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30294 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 191 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184689 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/184689
CABOZANTINIB COMPOSITIONS AND METHODS OF USE Apr 20, 2025 Pending
Array ( [id] => 20150400 [patent_doc_number] => 20250250238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/184838 [patent_app_country] => US [patent_app_date] => 2025-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184838 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/184838
CABOZANTINIB COMPOSITIONS AND METHODS OF USE Apr 20, 2025 Issued
Array ( [id] => 20164990 [patent_doc_number] => 20250257036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/184766 [patent_app_country] => US [patent_app_date] => 2025-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184766 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/184766
Cabozantinib compositions and methods of use Apr 20, 2025 Issued
Array ( [id] => 20150400 [patent_doc_number] => 20250250238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => CABOZANTINIB COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/184838 [patent_app_country] => US [patent_app_date] => 2025-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19184838 [rel_patent_id] =>[rel_patent_doc_number] =>)
19/184838
CABOZANTINIB COMPOSITIONS AND METHODS OF USE Apr 20, 2025 Issued
Array ( [id] => 19983958 [patent_doc_number] => 20250122180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/999866 [patent_app_country] => US [patent_app_date] => 2024-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18999866 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/999866
DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF Dec 22, 2024 Pending
Array ( [id] => 19983958 [patent_doc_number] => 20250122180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/999866 [patent_app_country] => US [patent_app_date] => 2024-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5395 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18999866 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/999866
DERIVATIVES OF SUBSTITUTED MORPHOLINES AND USES THEREOF Dec 22, 2024 Pending
Array ( [id] => 20227141 [patent_doc_number] => 12415784 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Cabozantinib compositions and methods of use [patent_app_type] => utility [patent_app_number] => 18/938926 [patent_app_country] => US [patent_app_date] => 2024-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 31006 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18938926 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/938926
Cabozantinib compositions and methods of use Nov 5, 2024 Issued
Array ( [id] => 19707795 [patent_doc_number] => 20250017937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES [patent_app_type] => utility [patent_app_number] => 18/779430 [patent_app_country] => US [patent_app_date] => 2024-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18779430 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/779430
MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES Jul 21, 2024 Pending
Array ( [id] => 19707795 [patent_doc_number] => 20250017937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES [patent_app_type] => utility [patent_app_number] => 18/779430 [patent_app_country] => US [patent_app_date] => 2024-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18779430 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/779430
MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES Jul 21, 2024 Pending
Array ( [id] => 19584955 [patent_doc_number] => 20240382512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof [patent_app_type] => utility [patent_app_number] => 18/771270 [patent_app_country] => US [patent_app_date] => 2024-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18771270 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/771270
Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof Jul 11, 2024 Pending
Array ( [id] => 19403497 [patent_doc_number] => 20240287008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES [patent_app_type] => utility [patent_app_number] => 18/643948 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643948 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/643948
METHOD FOR THE SYNTHESIS OF 3-R-1,4,2-DIOXAZOL-5-ONES Apr 22, 2024 Pending
Array ( [id] => 19543104 [patent_doc_number] => 20240360140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/620225 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63322 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620225 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/620225
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS Mar 27, 2024 Pending
Array ( [id] => 20256058 [patent_doc_number] => 12428401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same [patent_app_type] => utility [patent_app_number] => 18/618379 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 3057 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/618379
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same Mar 26, 2024 Issued
Array ( [id] => 20256058 [patent_doc_number] => 12428401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same [patent_app_type] => utility [patent_app_number] => 18/618379 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 3057 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/618379
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same Mar 26, 2024 Issued
Array ( [id] => 20156951 [patent_doc_number] => 12383549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders [patent_app_type] => utility [patent_app_number] => 18/617723 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4329 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617723 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/617723
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders Mar 26, 2024 Issued
Array ( [id] => 20156951 [patent_doc_number] => 12383549 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders [patent_app_type] => utility [patent_app_number] => 18/617723 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4329 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18617723 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/617723
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders Mar 26, 2024 Issued
Array ( [id] => 20256058 [patent_doc_number] => 12428401 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same [patent_app_type] => utility [patent_app_number] => 18/618379 [patent_app_country] => US [patent_app_date] => 2024-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 14 [patent_no_of_words] => 3057 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18618379 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/618379
Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same Mar 26, 2024 Issued
Array ( [id] => 19554793 [patent_doc_number] => 20240366585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS) [patent_app_type] => utility [patent_app_number] => 18/613641 [patent_app_country] => US [patent_app_date] => 2024-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18613641 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/613641
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS) Mar 21, 2024 Pending
Menu